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Abstract
Background
Excess adiposity is a risk factor for poorer cancer survival, but there is uncertainty over
whether losing weight reduces the risk. We conducted a critical review of the literature
examining weight loss and mortality in overweight or obese cancer survivors.
Methods
We systematically searched PubMed and EMBASE for articles reporting associations
between weight loss and mortality (cancer-specific or all-cause) in overweight/obese
patients with obesity-related cancers. Where available, data from the same studies on non-
overweight patients were compared.
Results
Five articles describing observational studies in breast cancer survivors were included. Four
studies reported a positive association between weight loss and mortality in overweight/
obese survivors, and the remaining study observed no significant association. Results were
similar for non-overweight survivors. Quality assessment indicated high risk of bias across
studies.
Conclusions
There is currently a lack of observational evidence that weight loss improves survival for
overweight and obese cancer survivors. However, the potential for bias in these studies is
considerable and the results likely reflect the consequences of disease-related rather than
intentional weight loss. There is a need for stronger study designs, incorporating measures
of intentionality of weight loss, and extended to other cancers.
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Introduction
Overweight and obesity are highly prevalent [1] and associated with increased risk of a number
of the most common cancers [2–4]. There is convincing evidence that having a higher body
mass index (BMI) increases the risk of developing cancers of the uterus, gallbladder, kidney,
colon, cervix, and breast (in postmenopausal women) [3,4]. Overweight and obese individuals
are also probably at higher risk of liver cancer, and some evidence suggests they may also be at
increased risk of cancers of the oesophagus, rectum, and ovary, as well as leukaemia, non-
Hodgkin lymphoma, and multiple myeloma [3,4]. A recent study estimated that 3.6% of can-
cer cases diagnosed worldwide in 2012 were attributable to high BMI [5]. As such, many can-
cer survivors are overweight or obese at the time of diagnosis.
Advances in cancer screening and treatment mean that cancer survivors are living longer
[6] and they are seeking information about how lifestyle factors may influence their prognosis
[7–9]. For those who are overweight or obese, the potential implications of losing weight are
particularly relevant. In the general population, a desire to weigh less is ubiquitous among
overweight and obese individuals, and a substantial proportion report trying to lose weight
[10–14]. Carrying excess weight has been identified as a risk factor for recurrence, second pri-
mary cancers, reduced treatment effectiveness, treatment-related complications, and mortality
[15–27], and consequently a cancer diagnosis may serve as an added motivation to lose weight.
There has been relatively little intervention research into the effect of weight loss on cancer
outcomes. Two large trials of dietary change in breast cancer survivors–the Women’s Inter-
vention Nutrition Study (WINS) [28] and the Women’s Healthy Eating and Lifestyle (WHEL)
study [29]–produced findings suggestive of a favourable effect of weight loss on recurrence.
Both studies achieved positive changes in diet in the intervention group, but intervention par-
ticipants in WINS also lost weight. Analyses of cancer outcomes found lower cancer recur-
rence rates in the intervention group in WINS. Smaller randomised controlled trials (RCTs)
examining associations between weight loss and cancer-related biomarkers in overweight and
obese survivors have provided evidence consistent with benefits on progression and recur-
rence [30–33], and further research is underway to explore these changes in more detail [34–
40]. However, although these studies are supportive of the idea that weight loss could improve
cancer outcomes, none has yet directly examined whether losing weight confers a survival
advantage.
In this article we systematically review the available evidence on the relationship between
weight loss and mortality in overweight and obese cancer survivors. Our aim was to establish
whether weight loss conferred a mortality advantage for overweight and obese cancer survi-
vors. For comparison, we included findings on the association between weight loss and mor-
tality in non-overweight cancer survivors where it was reported within the same studies. Based
on a critical review of the existing literature, gaps are identified and recommendations made
for future directions in research and practice.
Method
Search strategy
The review methodology was developed in keeping with PRISMA guidelines for systematic
reviews S1 Table. We systematically searched, with no language restrictions, PubMed and
EMBASE (from their commencements through May 2014, and later updated to April 2016)
for studies of the association between weight loss and mortality in overweight and obese cancer
survivors. We intersected terms related to weight loss (weight loss, weight change, weight
reduction), mortality (mortality, survival, death), weight status (overweight, obese, obesity,
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BMI), and presence of cancer (cancer, malignan, neoplasm, carcinoma, tumour, tumor). All
fields were searched and results were filtered to include only studies of adult human popula-
tions. We supplemented the electronic searches with manual searches of the reference lists and
‘cited by’ lists of the selected articles and relevant reviews [41–53]. We looked for both clinical
trials and observational studies; the former are important for establishing a causal relationship
between weight loss and mortality, while the latter are useful for examining associations in
more representative samples of patients.
Study selection
We followed PRISMA guidelines on reporting items for systematic reviews [54]. The eligibility
of each article was assessed independently by two investigators (SEJ and MH). We included
studies if they reported the association between weight loss and either cancer-specific or all-
cause mortality (or survival) in overweight or obese cancer survivors. This included analyses of
solely overweight (BMI 25–29.9), obese (BMI30), or overweight and obese (BMI25)
patients, or analyses of patient groups across the whole weight spectrum that reported the asso-
ciation between weight loss and mortality stratified by weight status. We included studies in
which height and weight (to calculate BMI) had been self-reported, as well as studies where
they had been objectively measured.
In view of the limited number of studies available for review, we placed no restrictions on
the timing of the baseline weight measurement (i.e. before or shortly after diagnosis) as long as
the follow-up weight measurement was at least 12 months after diagnosis. The rationale for the
choice of the post-diagnosis follow-up point was to allow reasonable time for the acute effects
of treatment to have subsided.
Studies that examined cancer mortality in samples that were not limited to cancer survivors
and included healthy individuals or patients without cancer were excluded. We also excluded
studies of patients undergoing palliative treatment, studies that used recurrence-free survival
as their outcome (and did not also report overall/cancer-specific survival), and studies that
reported the interaction between weight loss and weight status but did not report any stratified
results.
Finally, because it is reasonable to consider that intentional weight loss would affect out-
comes in cancers with an aetiological link with obesity (e.g. endometrial or breast), but less
plausible for non-obesity-related cancers (e.g. nasopharyngeal), we also excluded studies
restricted to cancer types not convincingly associated with excess weight, as defined by the
World Cancer Research Fund [2] and results of Bhaskaran et al.’s 2014 Lancet paper [4].
Although some reviews provide suggestive evidence of an association between obesity and
poorer survival from cancer (e.g., see [24,26]), we do not believe it to be sufficient to warrant
inclusion of cancer types that do not have an aetiological relationship with obesity. In a report
by the World Cancer Research Fund on breast cancer survivorship, it was concluded that the
evidence that greater body fatness after diagnosis increases risk of mortality is limited (i.e. not
convincing or probable) [55]. A meta-analysis in prostate cancer survivors [24] raised substan-
tial questions about the observed association between BMI and survival, with the authors sug-
gesting it could be due to delayed diagnosis, more advanced stage at diagnosis, or treatment
difficulties, which would not be ameliorated by weight loss. As such, we cannot know whether
the poorer survival is directly attributable to excess weight or other factors. The results of that
review were also limited by high heterogeneity across studies and various issues relating to
missing data and failure to adjust for important confounders [24]. The authors highlighted the
need for studies of biomarkers and genetic markers related to adiposity and energy metabo-
lism to provide biological plausibility for a causal role of obesity in poorer cancer survival.
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Taking all of these factors into account, we did not feel that the evidence for an association
between obesity and poor survival in non-aetiologically-linked cancers was convincing enough
for studies in these cancer types to be included in our review.
Where we identified multiple records reporting the same analyses (e.g. a conference
abstract and a full publication) we included only the most recent article. Non-English records
retrieved were run through online translation programs to allow basic screening of the title
and abstract; none were identified as relevant for full-text consideration.
Data extraction
The following information was extracted independently from the included articles by two
investigators (SEJ and MH): study design, sample size and description, type of disease, disease
stage, length of follow-up, definition of weight loss, and the timing of weight assessments rela-
tive to diagnosis. We also extracted all-cause and cancer-specific mortality risk estimates and
95% confidence intervals (CI) associated with weight loss in overweight/obese survivors.
Where available, the equivalent risk estimates for non-overweight cancer survivors (BMI<25)
were also extracted to facilitate comparison. Where several models with different degrees of
adjustment for potential confounders were reported, we extracted the maximally adjusted risk
estimates. Where mortality was reported at several time points, we extracted data at the latest
time point to give the longest possible follow-up period. We attempted to obtain additional
information on each study as needed by contacting the lead or corresponding author of each
study.
Quality assessment
In the absence of an internationally accepted quality assessment tool for observational studies,
we developed a six-item evaluation framework to assess methodological quality. Specifically,
we sought to explore each study’s risk of bias, defined by the STROBE reporting recommenda-
tions as “a systematic deviation of a study’s result from a true value” that is typically “intro-
duced during the design or implementation of a study and cannot be remedied later” [56]. We
identified six potential biases relevant to our study question (selection bias, treatment alloca-
tion bias, immortal time bias, additional treatment bias, adherence bias, and survival time
bias/competing risk). We adopted a ‘signalling question’ and derived categories of high and
low risk of bias for each one (S2 Table). A diagram was constructed for the included studies to
illustrate contrasting biases.
Results
Search results
In total, 694 unique articles were identified (604 by the electronic searches and 90 from other
sources), which were reduced to 93 potentially eligible studies after screening the titles and
abstracts according to our inclusion and exclusion criteria (Fig 1). The majority of excluded
articles either did not focus on cancer or were not restricted to samples of cancer survivors.
After a careful assessment of the remaining articles, we excluded those that did not report the
association between weight loss and mortality, or did not present these data stratified by
weight status; those that focused on recurrence-free survival as an outcome; involved patients
receiving palliative treatment; had a follow-up time point for weight data that was less than 12
months post-diagnosis or was unclear; focused on cancers not convincingly associated with
weight; included individuals with a BMI <25 in the ‘overweight’ group; or were conference
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abstracts of included papers. After these exclusions, five articles remained for the final synthe-
sis [57–61].
Overview of included studies
All the articles included in our review describe observational studies published in English
between 2005 and 2012, with data collected between 1976 and 2008. No relevant clinical trials
were identified. Table 1 summarises the characteristics of the five included studies.
Study populations. All studies focused on survivors of breast cancer. Three studies drew
their samples from the USA [57,58,61], one was conducted in China [60], and one was cross-
Fig 1. Flow diagram of search strategy and study selection.
doi:10.1371/journal.pone.0169173.g001
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national, with samples from the USA and China [59]. In the latter study, the Chinese sample
was drawn from the same cohort as was used in another included study (the Shanghai Breast
Cancer Survival Study), and the USA sample was drawn from three different cohorts, two of
which were used in other included studies (Life After Cancer Epidemiology and the Nurses’
Health Study) and one of which was not reported on in any other included article (the Wom-
en’s Healthy Eating and Living Study). While the specific inclusion criteria varied by study,
there was considerable overlap between these study populations. Most cohorts in the included
studies specifically recruited breast cancer survivors; the exception was the Nurses’ Health
Study, a large prospective cohort study of female nurses.
The mean age of participants ranged from 54 to 59 years, and the total sample size ranged
from 1436 to 12915 cancer survivors. Each study grouped participants by weight status based
on BMI; the majority used a threshold of 25kg/m2 to distinguish overweight or obese (BMI
25) versus underweight or healthy weight (<25), but one classified participants as obese
(BMI30) or non-obese (BMI <30) [58]. The number of cancer survivors in the overweight/
obese category ranged from 409 to 5849 (18% to 54% of the total study sample) across studies.
Assessment of weight change. The assessment of weight and definition of weight loss var-
ied across studies. The majority relied on retrospective self-reports of weight at both time
points, but objective weight measurements were obtained at follow-up in two cohorts [59,60].
Three studies classified weight change according to the percentage change in body weight and
used a cut-off of 5% to indicate weight loss [57–59]. One study used weight change (>1kg) to
define weight loss [60], and one used BMI change (>0.5kg/m2) [61]. Two studies used multiple
categories of weight loss, defining a loss of 5–10% of initial body weight as ‘moderate’ weight
loss, and10% as ‘large’ weight loss [58,59]. None distinguished between intentional and
unintentional weight loss. In all studies, weight loss was compared to a weight stable referent
category, defined as weight change <5% [57–59], <1kg [60], or a BMI change <0.5kg/m2 [61].
Mortality end-points. Four studies reported all-cause mortality [57–60] and two reported
cancer-specific mortality [57,61]. Just one study reported associations with both all-cause and can-
cer-specific mortality [57]. The mean follow-up period was seven years (range 46–108 months).
Quality assessment
We formally assessed each study against six domains of potential for bias and the results are
shown in Fig 2. Two studies were considered to be broadly representative of the patient popu-
lation, with one recruiting participants through hospitals [57] and the other through a cancer
registry [60], each with high response rates (>80%). Of the remaining studies, one recruited
from two cancer registries but had a low response rate (<50%) [58], one comprised solely
nurses [61], and the other included multiple cohorts with low response rates as well as the
cohort of nurses [59]. All studies were observational so did not allocate participants to different
treatments. It is possible that weight change around the time of diagnosis had an influence on
which treatment participants received, so there was high risk of treatment allocation bias
across all studies. The exposure (weight loss) was generally self-reported after the period of
diagnosis and initial treatment. As such, data were likely to be selective for initial survivors
(immortal time bias), as well as having the bias associated with self-report. The issue of early
mortality was not addressed in the majority of studies, although one study attempted to collect
follow-up data (weight one year prior to death) from a proxy where possible for participants
who died between baseline and follow-up [57]. None of the studies examined the association
between weight loss and selection for adjuvant treatment, but there were varying degrees of
adjustment for treatment received; the risk of bias was therefore unclear. Data on adherence to
treatment were not reported in any study, so the risk of adherence bias was unclear. Just one
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study reported associations between weight loss and both cancer-specific and all-cause mortal-
ity, with similar findings [57]; all other studies reported one mortality outcome so the risk of
competing risk bias was unclear.
Overview of study results
Overweight and obese cancer survivors.
All-cause mortality: All four studies that reported data on all-cause mortality found that,
among overweight and obese breast cancer survivors, weight loss was associated with higher
mortality compared with weight stability, with hazard ratios (HRs) ranging from 1.40 to 4.75
[57–60] (Fig 3).
All models adjusted for age at diagnosis, chemotherapy, and oestrogen and progesterone
receptor status. Bradshaw et al. additionally adjusted for pre-diagnosis BMI, pre-diagnosis
adult weight gain, and tumour size. Caan et al. (2008) additionally adjusted for stage,
Fig 2. Assessment of studies’ risk of bias.
doi:10.1371/journal.pone.0169173.g002
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tamoxifen use, radiotherapy, number of positive nodes, smoking history, and physical activity,
and Caan et al. (2012) adjusted for race, menopausal status, stage, positive nodes, radiotherapy,
and smoking. Chen et al. adjusted for education, income, marital status, comorbidity, exercise
participation, intake of meats, cruciferous vegetables, and soy protein, time interval from diag-
nosis to study enrolment, menopausal status, menopausal symptoms, type of surgery, radio-
therapy, immunotherapy, tamoxifen use, and tumour-node metastasis stage.
In the two studies that subdivided participants who lost weight into ‘moderate’ and ‘large’
weight loss groups, only large weight loss (10% of initial weight) was significantly associated
with increased risk of mortality; there was no significant difference in mortality risk between
those who had a moderate weight loss (5–10% of initial weight) and those whose weight was
stable [58,59].
The results in the Chinese cohort [59,60] were similar to those observed in the majority of
the US cohorts, but more international studies are needed.
Cancer-specific mortality: Of the two studies that reported data on breast cancer-specific
mortality, just one observed a significant association with weight loss. That study [57] found
that overweight and obese women who lost weight were significantly more likely to die from
breast cancer (HR 7.84, 95% CI 3.36–21.2). The other study [61] found no significant associa-
tion between weight loss and breast cancer death (HR 0.81, 95% CI 0.57–1.15) (Fig 3).
Both studies adjusted for age and pre-diagnosis BMI, but Bradshaw et al. also adjusted for
pre-diagnosis adult weight gain, hormone receptor status, and tumour size, while Kroenke
et al. also adjusted for oral contraceptive use, parity and age at birth, menopausal status, age at
menopause, use of hormone replacement therapy, protein intake, and tamoxifen use. Other
notable differences between the studies were the study population and the definition of weight
Fig 3. Forest plot of risk estimates from observational studies of weight loss and mortality outcomes in overweight and obese (BMI
25) breast cancer survivors.
doi:10.1371/journal.pone.0169173.g003
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loss. Bradshaw et al.’s sample was recruited through hospitals after the point of diagnosis,
whereas Kroenke et al.’s sample was a cohort of nurses recruited prior to diagnosis (the Nurses’
Health Study). However, it should be noted that the Nurses’ Health Study cohort was also
included in the Breast Cancer Pooling Project which, consistent with Bradshaw et al.’s findings
for all-cause mortality, found that weight loss was associated with higher all-cause mortality
[59]. Weight loss was defined as a loss5% of initial body weight in Bradshaw et al.’s study,
and a BMI reduction of at least 0.5kg/m2 in Kroenke et al.’s study.
Non-overweight cancer survivors. Of the five studies described above, four also pre-
sented data for non-overweight individuals (BMI<25). The results were the same as for the
overweight and obese group. All three studies examining all-cause mortality found a higher
risk for non-overweight cancer survivors who lost weight relative to those whose weight was
stable, with HRs ranging from 1.59 to 7.43 [57,59,60]. Similarly, the results for breast cancer-
specific mortality were mixed, with one study reporting increased risk among individuals with
weight loss (HR 7.98, 95% CI 3.51–19.0) [57] and the other reporting no significant association
with breast cancer mortality (HR 1.41, 95% CI 0.95–2.09) [61] (Fig 4).
In each study, the risk estimate associated with weight loss was somewhat higher for the
non-overweight group than for the overweight and obese group. In addition, in contrast to the
overweight and obese group, even moderate weight loss (5–10%) was associated with an
increased all-cause mortality in non-overweight cancer survivors (USA: HR 1.59, 95% CI
1.17–2.16; China: HR 1.74, 95% CI 1.07–2.83) [59].
Discussion
Summary of findings
This systematic review examined the evidence from observational studies of overweight and
obese cancer survivors that weight loss confers a mortality benefit. We found relevant
Fig 4. Forest plot of risk estimates from observational studies of weight loss and mortality outcomes in non-overweight (BMI <25) breast
cancer survivors.
doi:10.1371/journal.pone.0169173.g004
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literature to be scarce; just five studies met our inclusion criteria, all of which focused on breast
cancer survivors. None of these provided evidence that weight loss improved survival for over-
weight and obese cancer survivors; rather, four studies found that weight loss was associated
with increased mortality, and the fifth found no significant association with mortality. Similar
results were observed in an additional study that examined weight loss and mortality in breast
cancer survivors with a BMI24 (and therefore did not meet our inclusion criteria), which
reported a significantly higher risk of mortality with weight loss [62]. To help contextualise
these findings, we also looked at the results for non-overweight cancer survivors where they
were reported in the included studies. The results were largely similar, with all but one study
finding weight loss to be associated with higher mortality and one finding no significant asso-
ciation; although effect sizes were slightly higher than for the overweight and obese survivors.
Intentionality of weight loss: a fundamental issue
A crucial limitation of the studies included in our review is that none was able to distinguish
between intentional and disease-related (unintentional) weight loss. Research in general popu-
lation samples (not cancer survivors) indicates that unintentional weight loss is associated with
increased risk of mortality whereas intentional weight loss has an overall neutral effect on sur-
vival [63]. In the context of breast cancer, both obesity and post-diagnostic weight gain have
been shown to significantly increase the risk of mortality [15,64], and intentional weight loss
in the general population has been shown to favourably affect numerous breast cancer-relevant
risk factors and potential mediators, such as circulating oestrogens, sex-hormone binding
globulin, inflammatory markers and insulin sensitivity [65], so one might expect to see a posi-
tive effect of intentional weight loss on survival.
Ideally, we would have limited the review to studies that looked at weight change entirely
post-treatment to try to minimise the prevalence of unintentional weight loss resulting from
disease or treatment, but we found none that met these criteria. Given the fact that several
studies in this review did not control for tumour stage, patients may have had metastatic breast
cancer at diagnosis and weight loss could have occurred as a result of their malignancy. Indeed,
the strongest association between weight loss and mortality was seen in a study that did not
adjust for disease stage [57]. Additionally, the majority of studies did not control for comor-
bidities, and cachexia occurs at later stages of many diseases, potentially confounding these
observations. The inclusion of unintentional weight loss in their analyses is a potentially major
source of bias which makes it impossible to draw conclusions regarding the safety of inten-
tional weight loss for breast cancer survivors.
Analyses of survival outcomes by amount of weight loss are suggestive of unintentional
weight loss driving significant associations with mortality. Large weight losses are unusual
from traditional weight loss methods [66] and so are likely to be a sign of unintentional weight
loss in this population group. In the two studies that examined mortality according to the
amount of weight lost, it was only the large weight losses (10% of initial body weight) that
were associated with increased mortality.
Integration with the wider literature
The findings of the reviewed literature are seemingly at odds with evidence that weight loss in
cancer survivors is associated with changes in biomarkers that are plausibly linked with can-
cer-related outcomes [28,30–33]. This is likely due to the findings of studies included in this
review almost certainly being driven by unintentional weight loss. None of the studies relating
weight loss to biomarker changes had mortality as an outcome in the original study, although
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one [28] observed lower mortality in the dietary intervention group (who also lost weight) as a
post-hoc observation.
The majority of breast cancer survivors will die from causes other than breast cancer
[67,68], with cardiovascular disease in particular accounting for a substantial proportion of
deaths [67]. Breast cancer survivors have increased risk of cardiovascular disease and other
competing sources of mortality such as second cancers [69,70], likely due to common risk fac-
tors such as obesity, as well as the impact of cancer treatments like anthracyclines and radia-
tion. Weight loss has been shown to reduce the risk of these competing sources of mortality in
other populations [71,72] and the same is likely true for women with breast cancer. Evidence
for an association between post-diagnostic weight gain and increased risk of breast cancer
recurrence and mortality [64] further call into question the biology which could underlie an
association between weight loss and increased mortality risk.
Aside from effects on mortality, obesity has also been shown to increase the risk of morbid-
ity in women with breast cancer. Surgical complications such as lymphedema, wound infec-
tions, poor wound healing, and unfavourable cosmetic outcomes with breast reconstruction
are all more common in obese women [73–75]. Obesity is also associated with neuropathy as a
result of chemotherapy, increased fatigue and reduced quality of life in women with breast
cancer [76–81]. More than two dozen weight loss intervention studies have been performed in
breast cancer populations, and these have shown that intentional weight loss leads to many
improvements in symptoms and side effects of cancer therapy in breast cancer survivors
[31,82–86]. These results indicate substantial benefits of weight loss for women with breast
cancer. Notably, these studies have also shown no suggestion of increased risk of breast cancer
recurrence or progression in women who lose weight.
Sources of bias
In addition to the lack of consideration of weight loss intention, there were also other limita-
tions and potential sources of bias in the extant literature. All the included studies focused on
survivors of breast cancer, so results may not extend to male cancer survivors or female survi-
vors of other cancers. In addition, the mean age of samples was relatively young at 54–59
years. The figures on breast cancer incidence in the UK indicate that around half of cases are
diagnosed over the age of 60 and a quarter over the age of 75 [87], so these results may not gen-
eralise to older cancer survivors. The substantial overlap in study samples across four of the
five studies we reviewed further limits the generalisability of findings, and may overinflate the
current state of the evidence. It should also be noted that timespan for data collection in the
included studies was from 1976 to 2008. Advances in treatment influencing survival may cause
a time effect, and this time effect may vary across the included studies.
The cohorts were not specifically designed for the purpose of evaluating weight loss, so the
analyses largely relied on self-reported data, and often with a recall component. While system-
atic under- or overestimation of weight should not substantially affect analyses of weight
change, underreporting weight may have led to underestimation of effects in the non-over-
weight group through the inclusion of some overweight participants in this category. Likewise,
the use of standard BMI cut-offs (as opposed to cut-offs adapted for Asian populations) to
define overweight and obesity in the Chinese samples in two of the studies may also have
resulted in effects in the non-overweight group being underestimated. In addition, the number
of participants within the samples who lost weight was small, particularly in the10% of base-
line body weight bracket, making it difficult to derive reliable estimates of effects.
The studies did not consistently control for other important confounders of the association
between weight loss and survival such as disease-related factors (e.g. stage, treatment, metastatic
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disease), health behaviours (e.g. physical activity, smoking), or comorbid health conditions, all
of which may contribute to explaining differences in mortality between weight change groups.
A number of the studies also failed to adjust for menopausal status despite significant associa-
tions with disease occurrence and recurrence and possible mortality [88,89].
Although all the studies stratified the results by weight status, none reported whether mean
BMI was higher among overweight and obese weight losers than non-losers (the reference
group). Given the evidence that being more overweight is associated with higher mortality
[50,90], and that more overweight people are more likely to be trying to lose weight [10–14], if
the group who lost weight were heavier at baseline, their risk would already be higher than the
reference group, and therefore any risk reduction associated with weight loss would be attenu-
ated. Only two studies attempted to control for this by adjusting for pre-diagnosis BMI.
The extent of potential bias in the studies we identified limits the insights they offer. Selec-
tion bias may be present in individual studies if the reasons for non-response are related to
weight loss or mortality, although it is difficult to establish the degree to which any cumulative
selection bias across studies influenced the results of this review. The results may also be biased
by immortal time bias, because participants had to have survived for a certain period in order
to have sufficient data for inclusion in the analyses. They could also be biased by between-
group differences in allocation or adherence to treatment if this was influenced by weight
change in the early post-diagnosis period. Most studies focused on all-cause mortality, pre-
cluding assessment of bias arising from non-cancer deaths.
Future research
There are several ongoing randomised trials that will examine the impact of weight loss on
breast cancer recurrence and survival. The Italian DIANA-5 trial [36] and the German SUC-
CESS-C trial [35] have completed recruitment, and in North America the ENERGY trial is
currently recruiting [39] and the BWEL trial is starting recruitment in August 2016 [40].
These trials will provide conclusive evidence on the impact of weight loss on breast cancer out-
comes, but further research is needed to extend the evidence base to other cancer sites.
In observational studies, it would be valuable to have better assessments of weight loss as an
exposure, with a move toward objective measurements of body weight. Some assessment of
intentionality is also needed. Defining intentionality is not easy, and will likely require more
than simply asking participants whether or not they were trying to lose weight. Weight loss
attempts are reported by a large majority of overweight and obese individuals [10–13], and so
they may misattribute unintentional weight loss to their own efforts. Studies that focus on the
period of time after treatment has been completed and weight has returned to normal could
help to limit the complication of unintentional weight loss for observational research in this
area. Future studies also need to take account of treatment allocation and adherence; both of
which might be influenced by weight status and weight change.
Limitations of the present review
This systematic review has several limitations. It was up-to-date at the time of submission, but
as this topic is one of growing interest, further relevant studies may have since been published.
We did not assess the likelihood of publication bias, and it is possible that analyses that found
a neutral effect of weight loss on mortality did not make it to publication. Many systematic
reviews use meta-analysis to increase the statistical power to examine whether or not an associ-
ation exists across published research results. We concluded that this was inappropriate in the
present review because of the small number of studies and their variation in relation to the
timing and definition of weight loss, adjustment for potential confounders, and overlap in the
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study populations. However, as the literature on this topic grows, such a meta-analysis may
become possible.
Conclusions
We were unable to identify any evidence on weight loss and mortality in non-breast cancer
populations. It is difficult to draw conclusions about the relationship between weight loss and
breast cancer outcomes from the limited observational data available, especially in terms of
breast cancer mortality. Ongoing definite trials testing the impact of purposeful weight loss on
breast cancer prognosis are important first steps for establishing whether weight loss confers a
mortality advantage for overweight and obese cancer survivors. However, trials with survivors
of other cancer types, and observational studies with improved assessments of weight, weight
loss intentionality and which take into account important confounders are also needed.
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